Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM, Stokoe D.

Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.

PMID:
23496764
2.

Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.

Huang L, Counter CM.

PLoS One. 2015 Apr 22;10(4):e0123918. doi: 10.1371/journal.pone.0123918.

3.

Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.

To MD, Rosario RD, Westcott PM, Banta KL, Balmain A.

Oncogene. 2013 Aug 22;32(34):4028-33. doi: 10.1038/onc.2012.404.

4.

Absolute Quantification of Endogenous Ras Isoform Abundance.

Mageean CJ, Griffiths JR, Smith DL, Clague MJ, Prior IA.

PLoS One. 2015 Nov 11;10(11):e0142674. doi: 10.1371/journal.pone.0142674.

5.

The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.

Ouerhani S, Elgaaied AB.

Cancer Biomark. 2011-2012;10(6):259-66. doi: 10.3233/CBM-2012-0254.

PMID:
22820081
6.

Comparison of liver oncogenic potential among human RAS isoforms.

Chung SI, Moon H, Ju HL, Kim DY, Cho KJ, Ribback S, Dombrowski F, Calvisi DF, Ro SW.

Oncotarget. 2016 Feb 9;7(6):7354-66. doi: 10.18632/oncotarget.6931.

7.

Rare codons regulate KRas oncogenesis.

Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM.

Curr Biol. 2013 Jan 7;23(1):70-5. doi: 10.1016/j.cub.2012.11.031.

8.

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D.

Cancer Cell. 2014 Feb 10;25(2):243-56. doi: 10.1016/j.ccr.2014.01.005.

9.

Differential oncogenic potential of activated RAS isoforms in melanocytes.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.

Oncogene. 2007 Jul 5;26(31):4563-70.

PMID:
17297468
10.

Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, Langmann T, Singer S, Klingseisen L, Schneider-Brachert W, Toll A, Real FX, Landthaler M, Hafner C.

Nat Genet. 2012 Jun 10;44(7):783-7. doi: 10.1038/ng.2316.

PMID:
22683711
11.

Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.

Vagaja NN, Parry J, McCallum D, Thomas MA, Bentel JM.

J Clin Pathol. 2015 Aug;68(8):657-60. doi: 10.1136/jclinpath-2015-202969.

PMID:
25926041
12.

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K.

Cancer Discov. 2013 Sep;3(9):993-1001. doi: 10.1158/2159-8290.CD-13-0096.

13.

GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples.

Halvey PJ, Ferrone CR, Liebler DC.

J Proteome Res. 2012 Jul 6;11(7):3908-13. doi: 10.1021/pr300161j.

14.

Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.

Janzarik WG, Kratz CP, Loges NT, Olbrich H, Klein C, Schäfer T, Scheurlen W, Roggendorf W, Weiller C, Niemeyer C, Korinthenberg R, Pfister S, Omran H.

Neuropediatrics. 2007 Apr;38(2):61-3.

PMID:
17712732
15.

BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment.

Czajkowski R.

Int J Dermatol. 2011 Feb;50(2):180-3. doi: 10.1111/j.1365-4632.2010.04675.x.

PMID:
21244382
16.
17.

PIK3CA, HRAS and KRAS gene mutations in human penile cancer.

Andersson P, Kolaric A, Windahl T, Kirrander P, Söderkvist P, Karlsson MG.

J Urol. 2008 May;179(5):2030-4. doi: 10.1016/j.juro.2007.12.040.

PMID:
18355852
18.

Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.

Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD.

Oncogene. 2000 Sep 28;19(41):4685-94.

19.

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S.

PLoS One. 2009 May 27;4(5):e5717. doi: 10.1371/journal.pone.0005717.

20.

Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo.

Fujita M, Norris DA, Yagi H, Walsh P, Morelli JG, Weston WL, Terada N, Bennion SD, Robinson W, Lemon M, Maxwell IH, Yohn JJ.

Melanoma Res. 1999 Jun;9(3):279-91.

PMID:
10465584
Items per page

Supplemental Content

Support Center